Page 311 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

a Other ethnic origins included Hispanic descent, mixed racial parentage, and unknown ethnic origin; b Other tumour types included anal cancer, oesophageal cancer, head and neck cancer, pancreatic cancer, bladder cancer, unknown primary tumour, vulva carcinoma, and several rare tumour types;
c WHO performance status was not specified for these patients, but was either 0, 1, or 2, as required by the study inclusion criteria.
Abbreviations: IQR: interquartile range; BSA: body surface area; DPD: dihydropyrimidine dehydrogenase; DPYD: gene encoding dihydropyrimidine dehydrogenase; WHO: world health organisation; NA: not applicable.
Figure 2. Manhattan plot
12
Genome-wide association study
Manhattan plot for association with severe fluoropyrimidine-induced toxicity (grades 3─5), including de covariates gender, age, baseline BSA and treatment type. Genome-wide significance of the association with the onset of severe fluoropyrimidine-induced toxicity is indicated by the upper dark red line (≤p-value of 5x10-8). Suggestive association is indicated by the lower red line (p-value of ≤5x10- 6). No SNPs were found to be associated with severe fluoropyrimidine-induced toxicity. Six SNPs were found to be suggestive for association with severe fluoropyrimidine-induced toxicity, shown in Table 2. Abbreviations: BSA: body surface area; SNPs: single nucleotide polymorphisms.
309